Investors

News & Publications

News Releases

News Releases

November 20, 2018
Arvinas To Present at the 30th Annual Piper Jaffray Healthcare Conference
NEW HAVEN, Conn. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that John G. Houston , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 30th
October 23, 2018
Arvinas to Present at Two Protein Degradation Conferences
NEW HAVEN, Conn. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced it will be presenting at two upcoming conferences focused on protein degradation.
September 26, 2018
Arvinas Announces Pricing of Initial Public Offering
NEW HAVEN, Conn. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade
March 20, 2018
Arvinas to Present at the 17th Annual Needham Healthcare Conference
NEW HAVEN, CT, March 20, 2018 – Arvinas LLC, a private biotechnology company creating a new class of drugs based on protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a company overview at the 17 th  Annual Needham